Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation

BACKGROUND: We tested the hypothesis that a 4-month course of adjuvant dabrafenib in stage IIIC BRAF-mutated melanoma would improve 2 year RFS from 24% to 51%, and that tumor-derived cell free DNA (cfDNA) in plasma would correlate with and predict recurrence. METHODS: Patients with stage IIIC BRAF V...

Descripción completa

Detalles Bibliográficos
Autores principales: Momtaz, Parisa, Harding, James J., Ariyan, Charlotte, Coit, Daniel G., Merghoub, Taha, Gasmi, Billel, You, Daoqi, Viale, Agnes, Panageas, Katherine S., Samoila, Aliaksandra, Postow, Michael A., Wolchok, Jedd D., Chapman, Paul B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739615/
https://www.ncbi.nlm.nih.gov/pubmed/29285228
http://dx.doi.org/10.18632/oncotarget.21072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739615/
https://www.ncbi.nlm.nih.gov/pubmed/29285228
http://dx.doi.org/10.18632/oncotarget.21072

Ejemplares similares